Clinical Trials · NCT02987348
Clinical Outcomes of Exenatide Versus Basal Insulin
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 18,000
- Start date
- Jun 2015
- Locations
- 1 site, United Kingdom
- Primary endpoint
- Changes from baseline in HbA1c (%)